Navigation Links
NIH Recovery Act awards enable crucial health research technologies
Date:10/21/2010

Leading-edge, shared technologies are an important component of advancing research to improve health. Specialized instruments such as high-powered electron microscopes, high-resolution mass spectrometers and supercomputers that rapidly process vast amounts of data can enable breakthrough discoveries in preventions, treatments and cures for diseases.

Thanks to the Recovery Act, more health scientists now will have access to these state-of-the-art devices, the National Institutes of Health announced today. Through its National Center for Research Resources (NCRR), NIH has awarded $300 million in shared instrumentation grants.

In total, NCRR awarded more than 450 Recovery Act instrumentation grants to groups of NIH-funded scientists in 42 states and the District of Columbia. The grants, which range from $100,000 to $8 million, enable the purchase of technology that is vital to promising research projects.

"These Recovery Act awards make world class resources available to scientists nationwide," said NIH Director Francis S. Collins, M.D., Ph.D. "More researchers now will have access to the latest technologies that accelerate the pace of biomedical research, ultimately leading to new advances and treatments for diseases."

Following are three types of technologies and instruments funded by these grants, all of which have the potential to enhance a wide variety of biomedical research in many disease areas.

  • Researchers at the University of Minnesota in Minneapolis will use a $7.8 million grant to purchase components of a 10.5 Tesla whole-body magnetic resonance imaging system. This instrument will be the most powerful of its kind in the world, providing scientists with unprecedented views inside the human body. In the past two decades, researchers have made great strides in developing instruments with increasingly powerful magnetic fields that can zoom in on finer structures. The 10.5 Tesla magnet will push the technology even further and allow them to see more details of the human brain, as well as the human torso and extremities, thereby improving disease detection and treatment monitoring.

  • Using nearly $8 million, investigators at the University of Maryland, Baltimore have purchased a powerful 950 megahertz nuclear magnetic resonance spectrometer, to study human tissues and cells in atomic detail. Researchers from across the mid-Atlantic region will use this imaging device one of just two in the country to identify new ways to treat cancer, HIV/AIDS and heart disease, and to design more effective drugs. These spectrometers apply strong magnetic fields to biological samples to extract information about the identity and locations of atoms within proteins, fats and other molecules. By analyzing cells and tissues in such detail, researchers can learn about disease processes and possible treatments.

  • To examine cell division in detail, researchers at the University of Washington in Seattle will use a nearly $215,000 award to develop a multicolor total internal reflection fluorescence microscope. This instrument overcomes a major obstacle of conventional fluorescence microscopy that leads to blurry images when fluorescent target molecules inside a cell are too close to one another. Using this microscope, researchers at the University of Washington plan to obtain detailed views of the cellular apparatus components responsible for pulling apart chromosomes as cells divide. The insights gained promise to revolutionize the design of cancer drugs that target these components.

"Innovative research requires access to the latest technologies," said NCRR Director Barbara Alving, M.D. "These high-performance tools will ensure that NIH-funded investigators remain at the forefront of modern biomedical research."

NCRR's instrumentation grants fall under two categories. The Shared Instrumentation Grant (SIG) program provides funding for NIH-supported investigators to obtain equipment in the $100,000 to $600,000 price range. Examples of instrumentation supported by SIG funding include nuclear magnetic resonance systems, cell sorters, and protein and DNA sequencers. The High-End Instrumentation (HEI) grant program supports the purchase of sophisticated research equipment costing more than $750,000 with a ceiling of $2 million. For the Recovery Act awards, the floor for the HEI program was adjusted to $600,000 and the ceiling was raised to $8 million to accommodate a broader range of technologies. Instruments in this price range include high-resolution mass spectrometers, electron microscopes and supercomputers.

SIG and HEI grants are highly cost-effective because the programs require that each instrument be shared by at least three researchers. Approximately eight to 10 investigators will share each of the instruments funded through this Recovery Act program, enabling a reach of more than 3,500 scientists nationwide.


'/>"/>

Contact: Bobbi Gardner
bobbi.gardner@nih.gov
310-443-9919
NIH/National Center for Research Resources
Source:Eurekalert

Related medicine news :

1. Recovery Act's One Year Anniversary -- 2009 Was Just the Opening Act
2. Federal Recovery Funds Allow Eries Shriners Hospital to Reduce Energy Costs, Invest Savings in Patient Care
3. U.S. Senate Urgently Needs to Extend Medicaid Match in Economic Recovery Legislation
4. Alliance, Inc. Receives Centers of Excellence in Recovery Grant
5. De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V
6. San Francisco Plastic Surgeon Releases Plastic Surgery Patient Recovery Blog
7. Passages to Recovery Outdoor Addiction Treatment Program Achieves Joint Commission Accreditation
8. Economic Recovery and New Healthcare Legislation: The Stars Are Aligned for Increased Adoption of HR Management Systems (HRMS)
9. New Laser Treatment Offers Revolutionary Response to Aesthetic Procedure Candidates' Number One Concern: Recovery Time
10. Arizona Surgeon Performs Hip Replacement Surgery with Fast Recovery, Less Pain
11. Addiction and Recovery: Life Force Dallas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: